Devan Szczepanski
Emergency Medicine · Lafayette, LANPI 1467751354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 347 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,746 and has fallen 97.6% since, to $42 in 2025. Among emergency medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 347 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- Novo Nordisk$436
- Lilly USA, LLC$415
- Sanofi-aventis U.S. LLC$263
- Boehringer Ingelheim$227
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,11699%
- Education$381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 64 | $1,201 |
| AbbVie(2 entities) | 98 | $1,023 |
| Novo Nordisk | 34 | $436 |
| Lilly USA, LLC | 29 | $415 |
| Sanofi-aventis U.S. LLC | 20 | $263 |
| Boehringer Ingelheim | 16 | $227 |
| Arbor Pharmaceuticals, Inc. | 12 | $188 |
| AstraZeneca | 10 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $164 |
| Teva Pharmaceuticals USA, Inc. | 8 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $129 |
| Promius Pharma LLC | 1 | $114 |
| Eisai Inc. | 6 | $108 |
| Biohaven Pharmaceuticals, Inc. | 5 | $90 |
| Shire North American Group Inc | 4 | $70 |
| Ironshore Pharmaceuticals Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Millicent US Inc | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Boston Scientific | 2 | $27 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Stryker | 1 | $22 |
| Pfizer | 1 | $20 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $18 |
| GSK | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $14 |
| Qiagen, LLC | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRIANEX 0.05%$114
- Promiseb Complete$114
- Sernivo$114
How this compares
$5,154 in reported general payments places this provider in the 95th percentile of 881 emergency medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluoxetine Hcl | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Lafayette
- Tonya BoudreauxLafayette$1K
- Rochelle DuplechinLafayette$1K
- Fred WillisShreveport$427K
- Bryant BoydShreveport$83K
- Thomas ArnoldShreveport$48K
- Noah PoresNew Orleans$34K
- Granville MorseNew Orleans$32K
- Claude DantonioNew Orleans$26K
- Guy LefortCut Off$24K
- Mark DemanuelleDonaldsonville$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.